Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End

  • Upon reviewing Protagenic Therapeutics Inc's PTIX Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND.
  • The application sought approval to start a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression. 
  • The agency has asked the Company to provide clinical sites with ready-to-inject clinical vials rather than providing site pharmacies with drug substances to be formulated locally.
  • Protagenic is immediately implementing the necessary change; hence it expects to refile its IND and commence patient enrollment in Q4 of 2021 against 1H of 2021.
  • In April, the Company closed NASDAQ uplisting and a $13.2 million public offering.
  • PT00114 is a teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulating stress response in the brain.
  • Price Action: PTIX shares closed at $2.46 on Friday.
  • Related content: Benzinga's Full FDA Calendar.

Posted In: BriefsdepressionPhase 1 TrialBiotechNewsPenny StocksHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.